RNA transfection

EQS-News: LEON successfully completes development of its innovative reactor for more efficient production of lipid nanoparticles

Retrieved on: 
Sunday, January 22, 2023
LNP, CSO, RNA transfection, Research, CFO, API, Gesellschaft mit beschränkter Haftung, Particle size, Conference, Transfection, Nanotechnology, LEON, Fine chemical

With all prerequisites set for serial production, the proprietary reactor will now provide excellent inter-device reproducibility of nanoparticle features.

Key Points: 
  • With all prerequisites set for serial production, the proprietary reactor will now provide excellent inter-device reproducibility of nanoparticle features.
  • Christian Nafe, CFO of LEON, commented: “The results of our reactor studies strongly support that LEON has reached an important milestone in product development and is well on its way towards commercialization.
  • Consequently, we can measure excellent data in terms of particle size reproducibility and distribution,” added Dr. Frank Stieneker, CSO of LEON.
  • Please contact us via e-mail or LinkedIn to set up a meeting with CFO Christian Nafe and advisor Dr. Klaus Binder.

EQS-News: CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs

Retrieved on: 
Sunday, January 22, 2023
CET, RNA transfection, Influenza, CureVac, EST, COVID-19, GSK, WHO, CVAC, Infection, Omicron, Safety, Webcast, RNA, Vaccine, Communications satellite

Based on these preliminary data, development of modified mRNA COVID-19 and flu vaccine candidates will be advanced to the next stage of clinical testing in 2023.

Key Points: 
  • Based on these preliminary data, development of modified mRNA COVID-19 and flu vaccine candidates will be advanced to the next stage of clinical testing in 2023.
  • Preliminary data from the modified, monovalent mRNA vaccine candidates CV0501 for COVID-19 and Flu-SV-mRNA for flu are being disclosed today, with final Phase 1 data to be published in due course.
  • The second-generation mRNA backbone using modified mRNA was selected as the preferred technology for further clinical development in the seasonal flu vaccine program.
  • Interim data support the progression of the modified second-generation mRNA technology for the development of a multivalent mRNA flu vaccine.

BioNTech Announces Strategic Partnership with UK Government to Provide up to 10,000 Patients with Personalized mRNA Cancer Immunotherapies by 2030

Retrieved on: 
Friday, January 6, 2023
Cancer, Clinical trial, Government, Corporate governance in the United Kingdom, UK Research and Innovation, RNA transfection, Drug development, Research, Pfizer, COVID-19, Private sector, COVID-19 vaccine, Genomics, Intellectual property, BNTX, Neoplasm, Patient, Infection, Medicine, National Health Service, Malaria, Research and development, Investment, Memorandum of understanding, BioNTech, Union, United Kingdom, Human, Vaccine, Pharmaceutical industry

As part of the MoU, the Company and the UK Government plan to accelerate trial site and patient recruitment for clinical candidates of BioNTech’s pipeline for personalized mRNA cancer immunotherapies and infectious disease vaccines.

Key Points: 
  • As part of the MoU, the Company and the UK Government plan to accelerate trial site and patient recruitment for clinical candidates of BioNTech’s pipeline for personalized mRNA cancer immunotherapies and infectious disease vaccines.
  • To achieve this, the parties plan to utilize the UK’s clinical trial network, genomics and health data assets.
  • BioNTech intends to design and roll out randomized trials in adjuvant or metastatic settings with registrational potential for the Company’s personalized mRNA cancer immunotherapies in the UK.
  • In 2012, the first mRNA-based personalized cancer therapy developed by BioNTech was administered in a first-in-human trial.

CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

Retrieved on: 
Thursday, January 5, 2023
Protein, Biotechnology, RNA transfection, Therapy, Research, Science, Patient, Biology, Infection, Degenerative disease, MRNA, Vaccine, RNA, Pharmaceutical industry, Moderna

SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ: CTMX), a leader in the field of conditionally activated oncology therapeutics and Moderna, Inc. (NASDAQ: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a collaboration and licensing agreement to create investigational mRNA-based conditionally activated therapies utilizing Moderna’s mRNA technologies and CytomX’s Probody® therapeutic platform.

Key Points: 
  • The research collaboration will leverage core scientific advances at Moderna and CytomX.
  • CytomX’s Probody technology enables proteins to be activated locally in diseased tissue, while remaining masked in systemic circulation.
  • “We are excited to enter this collaboration with CytomX to combine our technologies and to potentially bring mRNA-based conditionally activated therapies to patients,” said Rose Loughlin, Ph.D., Moderna’s Senior Vice President for Research and Early Development.
  • “Moderna’s global impact has shown the enormous power of mRNA and we look forward to working closely with our newest collaborator to bring novel, mRNA-based conditionally activated therapeutics to patients with unmet medical needs.”

CytomX Therapeutics Provides Business Update and Outlines 2023 Company Priorities

Retrieved on: 
Thursday, January 5, 2023
Melanoma, Therapeutic index, Anemia, Protein, RNA transfection, Research, APC, Astellas Pharma, Camptothecin, Platinum, Diarrhea, HIV disease progression rates, Immunotherapy, PR, Colorectal cancer, Amgen, Nausea, Cancer, Patient, Tumor microenvironment, Bristol Myers Squibb, Ipilimumab, Infection, Cytokine, Degenerative disease, BMS, Febrile neutropenia, Regeneron Pharmaceuticals, ADC, Safety, Fatigue, Therapy, Webcast, IND, Triple-negative breast cancer, Neutropenia, Esophageal, Toxic leukoencephalopathy, ESMO, SD, Vaccine, Nivolumab, CR, Control, Epithelial cell adhesion molecule, Trae tha Truth, Pharmaceutical industry, Oil, Moderna, HNSCC, TCB

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced its 2023 company priorities and provided a pipeline update which included anticipated milestones for 2023, recent progress and achievements in its wholly owned and collaboration pipeline, and a data update for the Phase 2, CX-2029 cohort expansion study. The company will host a call with investors today to review the CX-2029 cohort expansion study data and potential key pipeline events for 2023.

Key Points: 
  • The company plans to rapidly advance this potentially best-in-class program towards clinical evaluation with an IND filing targeted for the second half of 2023.
  • The company anticipates filing an IND for this novel ADC in the second half of 2023.
  • CytomX enters 2023 in a strong strategic position and with significant momentum in its pipeline.
  • CytomX management will host a conference call and a simultaneous webcast today, January 5th 2023 at 5 p.m.

Homology Medicines Provides Update on pheEDIT and juMPStart Clinical Trials and Announces Expected 2023 Milestones, Including Initial Data Read-Outs from Both Programs

Retrieved on: 
Wednesday, January 4, 2023
Immunosuppression, Clinical trial, Homologous recombination, Steroid, RNA transfection, Gene editing, NAB, AAV, MPS, MLD, Hunter syndrome, PKU, PNH, Genome, MPS II, IND, JumpStart, Paroxysmal nocturnal hemoglobinuria, PAH, Phenylketonuria, Pharmaceutical industry, Vaccine

BEDFORD, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today enrollment and site status updates from the pheEDIT Phase 1 gene editing trial with HMI-103 for phenylketonuria (PKU) and the juMPStart Phase 1 gene therapy trial with HMI-203 for Hunter syndrome (MPS II).

Key Points: 
  • Homology expects to provide initial data from the trial mid-year 2023.
  • There are nine active clinical trial sites with more expected to be initiated throughout 2023.
  • The juMPStart trial has five clinical sites in the U.S. and Canada with more expected to be initiated, and initial data is expected in the second half of 2023.
  • Importantly, we plan to share initial clinical data from both trials in 2023, including the first data from our nuclease-free gene editing technology in humans.”
    Homology shared new preclinical data today supporting the immunosuppression regimen incorporated in both the pheEDIT and juMPStart trials.

Eterna Therapeutics Appoints Matt Angel, Ph.D. as Chief Executive Officer and President

Retrieved on: 
Wednesday, January 4, 2023
Biotechnology, H5 (US company), RNA transfection, Gene editing, Therapy, Princeton University, Interim, United States Air Force Scientific Advisory Board, Entrepreneurship, ERNA, Patent, IPS, Massachusetts Institute of Technology, Management, Eterna

CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. ( Nasdaq: ERNA ) (“Eterna” or the “Company”), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announced the appointment of Matt Angel, Ph.D. as Chief Executive Officer (“CEO”) and President.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. ( Nasdaq: ERNA ) (“Eterna” or the “Company”), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announced the appointment of Matt Angel, Ph.D. as Chief Executive Officer (“CEO”) and President.
  • Dr. Angel has served as Interim CEO and President of Eterna since May 2022 and will continue to serve on the Company's Board of Directors.
  • In addition to his role at Eterna, Dr. Angel serves as Co-Founder, Chairman and CEO of Factor Bioscience Inc., and Co-Founder and Scientific Advisory Board Chair of Exacis Biotherapeutics.
  • He previously served as Co-Founder and Chief Scientific Officer of Novellus Therapeutics, which was acquired by Eterna in 2021.

Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates

Retrieved on: 
Wednesday, January 4, 2023
Cancer, Organic acid, LNP, Amine, Daewoong Pharmaceutical, Pharmacokinetics, RNA transfection, Research, PEG, Patient, KRX, Therapy, Quality of life, RNA, Lipid, Vaccine, Pharmaceutical industry

Research collaboration leverages Oncorus’ proprietary ionizable amines, PEG lipids, LNP formulations, process development and manufacturing together with Daewoong’s mRNA expertise

Key Points: 
  • Research collaboration leverages Oncorus’ proprietary ionizable amines, PEG lipids, LNP formulations, process development and manufacturing together with Daewoong’s mRNA expertise
    ANDOVER, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, and Daewoong Pharmaceutical Co., Ltd. (KRX: 069620), a leading South Korean pharmaceutical company, today announced a research collaboration for the discovery and development of novel lipid nanoparticle (LNP) formulations for mRNA drug candidates.
  • Under the terms of the collaboration, Oncorus and Daewoong will conduct joint research to identify and evaluate formulations of Daewoong’s mRNAs encapsulated in Oncorus’ proprietary LNPs.
  • Oncorus will develop formulated drug candidates at its state-of-the-art manufacturing facility in Andover, Massachusetts.
  • In multiple preclinical models involving repeat intravenous (IV) dosing, Oncorus’ formulations have demonstrated improved tolerability, an enhanced therapeutic window and consistent pharmacokinetics compared to approved formulations.

LEON successfully completes development of its innovative reactor for more efficient production of lipid nanoparticles

Retrieved on: 
Tuesday, January 3, 2023
LNP, CSO, RNA transfection, Research, CFO, API, Gesellschaft mit beschränkter Haftung, Particle size, Conference, Transfection, Nanotechnology, LEON, Fine chemical

With all prerequisites set for serial production, the proprietary reactor will now provide excellent inter-device reproducibility of nanoparticle features.

Key Points: 
  • With all prerequisites set for serial production, the proprietary reactor will now provide excellent inter-device reproducibility of nanoparticle features.
  • Christian Nafe, CFO of LEON, commented: “The results of our reactor studies strongly support that LEON has reached an important milestone in product development and is well on its way towards commercialization.
  • Consequently, we can measure excellent data in terms of particle size reproducibility and distribution,” added Dr. Frank Stieneker, CSO of LEON.
  • Please contact us via e-mail or LinkedIn to set up a meeting with CFO Christian Nafe and advisor Dr. Klaus Binder.

Valneva Reports Further Heterologous Booster Data for its inactivated COVID-19 vaccine

Retrieved on: 
Friday, December 30, 2022
VLA, Pfizer–BioNTech COVID-19 vaccine, Euronext Paris, AstraZeneca, COVID-19, MHRA, RNA transfection, Moderna, EMA, Saint-Herblain, Vaccine, VLA2001

Saint-Herblain (France), December 30, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further heterologous booster data from an exploratory, small clinical study for its inactivated COVID-19 vaccine, VLA2001.

Key Points: 
  • Saint-Herblain (France), December 30, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further heterologous booster data from an exploratory, small clinical study for its inactivated COVID-19 vaccine, VLA2001.
  • The data show that a booster dose of VLA2001 was well tolerated in previously BNT162b2 (Pfizer/BioNTech)- or mRNA 1273 (Moderna)-vaccinated participants, confirming the favorable safety profile of VLA2001 seen across all studies – including in homologous or heterologous booster settings2.
  • The Company previously reported positive heterologous booster results following primary vaccination with ChAdOx1-S (AstraZeneca) in August 20223 and positive homologous booster results at the end of December 20214.
  • Valneva is currently seeking regulatory approval for VLA2001 as a homologous booster as well as heterologous booster in ChAdOx1-S (AstraZeneca) primed individuals which may support the Company in deploying its inventory in international markets5.